Page last updated: 2024-11-13

kj-pyr-9

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

KJ-Pyr-9: antineoplastic; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID85855478
CHEMBL ID4238599
SCHEMBL ID16792502
MeSH IDM000599953

Synonyms (17)

Synonym
kj pyr 9
4-[2-(2-furanyl)-6-(4-nitrophenyl)-4-pyridinyl]benzamide
581073-80-5
AKOS025293493
CS-5459
HY-19735
SCHEMBL16792502
4-(2-(furan-2-yl)-6-(4-nitrophenyl)pyridin-4-yl)benzamide
EN300-203116
kj-pyr-9
A915298
4-[2-(furan-2-yl)-6-(4-nitrophenyl)pyridin-4-yl]benzamide
F81785
MS-26350
CHEMBL4238599 ,
bdbm50463126
AKOS040741916
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Myc proto-oncogene proteinHomo sapiens (human)IC50 (µMol)1.00001.00005.73259.6700AID1398268
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Myc proto-oncogene proteinHomo sapiens (human)Kd0.00880.00651.12532.8000AID1398267; AID1618187; AID1618188
Protein maxHomo sapiens (human)Kd0.50670.01340.01340.0134AID1618188; AID1618189
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
positive regulation of cell population proliferationMyc proto-oncogene proteinHomo sapiens (human)
regulation of gene expressionMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationMyc proto-oncogene proteinHomo sapiens (human)
G1/S transition of mitotic cell cycleMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
MAPK cascadeMyc proto-oncogene proteinHomo sapiens (human)
branching involved in ureteric bud morphogenesisMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of mesenchymal cell proliferationMyc proto-oncogene proteinHomo sapiens (human)
chromatin remodelingMyc proto-oncogene proteinHomo sapiens (human)
intracellular iron ion homeostasisMyc proto-oncogene proteinHomo sapiens (human)
DNA damage responseMyc proto-oncogene proteinHomo sapiens (human)
response to xenobiotic stimulusMyc proto-oncogene proteinHomo sapiens (human)
response to gamma radiationMyc proto-oncogene proteinHomo sapiens (human)
regulation of cell cycle processMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of gene expressionMyc proto-oncogene proteinHomo sapiens (human)
regulation of telomere maintenanceMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of stress-activated MAPK cascadeMyc proto-oncogene proteinHomo sapiens (human)
protein-DNA complex disassemblyMyc proto-oncogene proteinHomo sapiens (human)
cellular response to UVMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of apoptotic processMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processMyc proto-oncogene proteinHomo sapiens (human)
fibroblast apoptotic processMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of monocyte differentiationMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of fibroblast proliferationMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of fibroblast proliferationMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of epithelial cell proliferationMyc proto-oncogene proteinHomo sapiens (human)
chromosome organizationMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of cell divisionMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of telomerase activityMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of transcription initiation by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
ERK1 and ERK2 cascadeMyc proto-oncogene proteinHomo sapiens (human)
response to growth factorMyc proto-oncogene proteinHomo sapiens (human)
cellular response to hypoxiaMyc proto-oncogene proteinHomo sapiens (human)
cellular response to xenobiotic stimulusMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of metanephric cap mesenchymal cell proliferationMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway by p53 class mediatorMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of miRNA transcriptionMyc proto-oncogene proteinHomo sapiens (human)
regulation of somatic stem cell population maintenanceMyc proto-oncogene proteinHomo sapiens (human)
regulation of transcription by RNA polymerase IIMyc proto-oncogene proteinHomo sapiens (human)
positive regulation of cell population proliferationMyc proto-oncogene proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIProtein maxHomo sapiens (human)
regulation of transcription by RNA polymerase IIProtein maxHomo sapiens (human)
positive regulation of DNA-templated transcriptionProtein maxHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIProtein maxHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificMyc proto-oncogene proteinHomo sapiens (human)
core promoter sequence-specific DNA bindingMyc proto-oncogene proteinHomo sapiens (human)
transcription coregulator bindingMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificMyc proto-oncogene proteinHomo sapiens (human)
DNA bindingMyc proto-oncogene proteinHomo sapiens (human)
protein bindingMyc proto-oncogene proteinHomo sapiens (human)
identical protein bindingMyc proto-oncogene proteinHomo sapiens (human)
protein-containing complex bindingMyc proto-oncogene proteinHomo sapiens (human)
protein dimerization activityMyc proto-oncogene proteinHomo sapiens (human)
E-box bindingMyc proto-oncogene proteinHomo sapiens (human)
DNA-binding transcription factor bindingMyc proto-oncogene proteinHomo sapiens (human)
SCF ubiquitin ligase complex bindingMyc proto-oncogene proteinHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingProtein maxHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificProtein maxHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificProtein maxHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificProtein maxHomo sapiens (human)
DNA bindingProtein maxHomo sapiens (human)
protein bindingProtein maxHomo sapiens (human)
identical protein bindingProtein maxHomo sapiens (human)
protein dimerization activityProtein maxHomo sapiens (human)
E-box bindingProtein maxHomo sapiens (human)
DNA-binding transcription factor bindingProtein maxHomo sapiens (human)
sequence-specific double-stranded DNA bindingProtein maxHomo sapiens (human)
DNA-binding transcription factor activityProtein maxHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nucleusMyc proto-oncogene proteinHomo sapiens (human)
nucleoplasmMyc proto-oncogene proteinHomo sapiens (human)
nucleolusMyc proto-oncogene proteinHomo sapiens (human)
cytoplasmMyc proto-oncogene proteinHomo sapiens (human)
Myc-Max complexMyc proto-oncogene proteinHomo sapiens (human)
RNA polymerase II transcription repressor complexMyc proto-oncogene proteinHomo sapiens (human)
chromatinMyc proto-oncogene proteinHomo sapiens (human)
protein-containing complexMyc proto-oncogene proteinHomo sapiens (human)
nucleusProtein maxHomo sapiens (human)
nucleoplasmProtein maxHomo sapiens (human)
dendriteProtein maxHomo sapiens (human)
Mad-Max complexProtein maxHomo sapiens (human)
Myc-Max complexProtein maxHomo sapiens (human)
chromatinProtein maxHomo sapiens (human)
protein-DNA complexProtein maxHomo sapiens (human)
MLL1 complexProtein maxHomo sapiens (human)
RNA polymerase II transcription regulator complexProtein maxHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1398282Clearance in C57Bl6 mouse at 10 mg/kg, iv by LC-MS analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398283Terminal half life in rat at 1 mg/kg, iv2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398287Volume of distribution at steady state in rat at 1 mg/kg, iv2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398268Binding affinity to ATG-Myc (unknown origin) expressed in CEF cells assessed as inhibition of microtumor formation2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398267Binding affinity to His-tagged Myc (unknown origin) expressed in Escherichia coli BL21 by Bio-FET analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398278AUC (0 to infinity) in C57Bl6 mouse at 10 mg/kg, iv by LC-MS analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398286MRT in rat at 1 mg/kg, iv2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398285AUMC (0 to infinity) in rat at 1 mg/kg, iv2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398276Drug metabolism in rat liver microsomes assessed as oxidized furan ion formation by measuring parent compound remaining at 5 uM after 45 mins by LC-MS analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398275Drug metabolism in rat liver microsomes assessed as oxidized furan ion formation by measuring parent compound remaining at 5 uM after 25 mins by LC-MS analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398281Volume of distribution at steady state in C57Bl6 mouse at 10 mg/kg, iv by LC-MS analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398284AUC (0 to infinity) in rat at 1 mg/kg, iv2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398263Binding affinity to His-tagged Myc (unknown origin) expressed in Escherichia coli BL21 at 10 uM by Bio-FET analysis relative to KJ-Pyr-92018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398262Solubility in pH 6 MES buffer by dynamic light scattering assay2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398279AUMC (0 to infinity) in C57Bl6 mouse at 10 mg/kg, iv by LC-MS analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398271Binding affinity to biotin-labeled EBOX dsDNA (unknown origin) at 10 uM measured over 2.5 mins by SPR analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398274Drug metabolism in rat liver microsomes assessed as oxidized furan ion formation by measuring parent compound remaining at 5 uM after 15 mins by LC-MS analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398265Binding affinity to His-tagged monomeric Max (unknown origin) expressed in Escherichia coli BL21 at 10 uM by Bio-FET analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398270Inhibition of biotin-labeled EBOX dsDNA binding to Myc-Max (unknown origin) at 10 uM preincubated for 15 mins followed by test compound-protein mixture addition to biotin-labeled EBOX dsDNA immobilized chip measured over 2.5 mins by SPR analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398272Drug metabolism in rat liver microsomes assessed as oxidized furan ion formation by measuring parent compound remaining at 5 uM after 3 mins by LC-MS analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398288Clearance in rat at 1 mg/kg, iv2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398264Binding affinity to His-tagged Myc/Max (unknown origin) expressed in Escherichia coli BL21 at 10 uM by Bio-FET analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398273Drug metabolism in rat liver microsomes assessed as oxidized furan ion formation by measuring parent compound remaining at 5 uM after 7 mins by LC-MS analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398280MRT in C57Bl6 mouse at 10 mg/kg, iv by LC-MS analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398277Terminal half life in C57Bl6 mouse at 10 mg/kg, iv by LC-MS analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
AID1398266Binding affinity to His-tagged dimeric Max (unknown origin) expressed in Escherichia coli BL21 at 10 uM by Bio-FET analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Synthetic molecules for disruption of the MYC protein-protein interface.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.38 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]